Entrada Therapeutics Stock Fundamentals
| TRDA Stock | USD 19.37 0.33 1.73% |
Entrada Therapeutics fundamentals help investors to digest information that contributes to Entrada Therapeutics' financial success or failures. It also enables traders to predict the movement of Entrada Stock. The fundamental analysis module provides a way to measure Entrada Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entrada Therapeutics stock.
At present, Entrada Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 16 M, whereas Selling General Administrative is forecasted to decline to about 19.2 M. Entrada | Select Account or Indicator |
Entrada Therapeutics Company Return On Equity Analysis
Entrada Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Entrada Therapeutics Return On Equity | 0.16 |
Most of Entrada Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entrada Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Entrada Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Entrada Therapeutics has a Return On Equity of 0.1642. This is 100.69% lower than that of the Biotechnology sector and 100.45% lower than that of the Health Care industry. The return on equity for all United States stocks is 152.97% lower than that of the firm.
Entrada Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Entrada Therapeutics's current stock value. Our valuation model uses many indicators to compare Entrada Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entrada Therapeutics competition to find correlations between indicators driving Entrada Therapeutics's intrinsic value. More Info.Entrada Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Entrada Therapeutics is roughly 2.36 . At present, Entrada Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Entrada Therapeutics' earnings, one of the primary drivers of an investment's value.Entrada Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entrada Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics of similar companies.Entrada Therapeutics is currently under evaluation in return on equity category among its peers.
Entrada Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Entrada Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Entrada Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Entrada Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0695 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | (1.11) % | ||||
| Current Valuation | 324.45 M | ||||
| Shares Outstanding | 37.42 M | ||||
| Shares Owned By Insiders | 12.82 % | ||||
| Shares Owned By Institutions | 80.83 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Book | 1.69 X | ||||
| Price To Sales | 3.31 X | ||||
| Revenue | 129.01 M | ||||
| EBITDA | (321 K) | ||||
| Net Income | (6.68 M) | ||||
| Cash And Equivalents | 244.25 M | ||||
| Cash Per Share | 7.81 X | ||||
| Total Debt | 68.23 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 14.05 X | ||||
| Book Value Per Share | 11.93 X | ||||
| Cash Flow From Operations | 139.8 M | ||||
| Short Ratio | 15.27 X | ||||
| Earnings Per Share | 1.44 X | ||||
| Target Price | 25.57 | ||||
| Number Of Employees | 177 | ||||
| Beta | -0.26 | ||||
| Market Capitalization | 712.48 M | ||||
| Total Asset | 469.19 M | ||||
| Retained Earnings | (194.97 M) | ||||
| Working Capital | 210.97 M | ||||
| Net Asset | 469.19 M |
About Entrada Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entrada Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 119 M | 105.8 M | |
| Total Revenue | 129 M | 135.5 M | |
| Cost Of Revenue | 99.9 M | 104.9 M | |
| Stock Based Compensation To Revenue | 0.09 | 0.08 | |
| Sales General And Administrative To Revenue | 0.23 | 0.20 | |
| Research And Ddevelopement To Revenue | 0.70 | 0.62 | |
| Capex To Revenue | 0.04 | 0.03 | |
| Revenue Per Share | 3.51 | 3.12 | |
| Ebit Per Revenue | (0.02) | (0.02) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out Entrada Therapeutics Piotroski F Score and Entrada Therapeutics Altman Z Score analysis. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.